Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: To describe and compare the delivery of medication therapy management (MTM) between Medicare beneficiaries with and without mental health conditions.
Design: Nationally representative cross-sectional study that used a 20% random sample of 2014 Medicare Parts A, B, and D data merged with a 100% sample of 2014 MTM data.
Setting And Participants: Medicare beneficiaries continuously enrolled in Parts A, B, and D in 2014 were included in this study. Comprehensive medication review (CMR) use and MTM delivery were examined among a subset of 825,003 MTM-enrolled beneficiaries.
Outcome Measures: Predisposing, enabling, and need characteristics were selected on the basis of the Andersen Behavioral Model of Health Services Use. Descriptive, bivariable, and multivariable logistic regression statistics were used to determine associations between beneficiary characteristics and MTM delivery.
Results: A total of 3,016,620 (43%) and 3,997,105 beneficiaries (57%) were categorized into mental health and nonmental health cohorts, respectively. MTM enrollment in the mental health cohort was significantly higher than that in the nonmental health cohort (17.4% vs. 7.5%, P < 0.001). However, once enrolled, a greater proportion of beneficiaries in the nonmental health cohort received CMRs (19.3% vs. 17.7%, P < 0.001). Patients in the mental health cohort were more likely to have hospitalization (22% vs. 9.2%, P < 0.001) or emergency department visit (25.2% vs. 11.5%, P < 0.001) and used more medications in 2014 (16 % vs. 12%, P < 0.001). The proportion of patients in the mental health cohort receiving a CMR in 2014 that had at least 1 medication-related problem (MRP) identified and resolved was higher than that of patients in the nonmental health cohort (24.8% vs. 20.6%, P < 0.001).
Conclusion: Although patients with mental health conditions are more often enrolled into MTM, they are less likely to receive a CMR once enrolled. Given that this population has higher medical complexity and a higher MRP burden following a CMR, opportunities exist for pharmacists to enhance MTM delivery in this population.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.japh.2019.12.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preclinical Ischemic Stroke Multicenter (PRISM) Trials Collective Statement: Opportunities, Challenges, and Recommendations for a New Era.
Stroke
September 2025
Department of Neurology, Yale School of Medicine, New Haven, CT (L.H.S.).
Preclinical stroke research faces a critical translational gap, with animal studies failing to reliably predict clinical efficacy. To address this, the field is moving toward rigorous, multicenter preclinical randomized controlled trials (mpRCTs) that mimic phase 3 clinical trials in several key components. This collective statement, derived from experts involved in mpRCTs, outlines considerations for designing and executing such trials.
View Article and Find Full Text PDFEffects of the Probiotics Lactobacillus rhamnosus DM163 and Lactobacillus delbrueckii DPUL-F36 on Anxiety-Related and Emotional Behaviors in Male Wistar Rats Under an Altered Light-Dark Cycle.
Brain Behav
September 2025
Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran.
Introduction: Anxiety and stress are prevalent mental health issues. Traditional drug treatments often come with unwanted side effects and may not produce the desired results. As an alternative, probiotics are being used as a treatment option due to their lack of specific side effects.
View Article and Find Full Text PDFSex- and gender-responsive management of anxiety disorders: future pathways for research, education, policy and practice.
Med J Aust
September 2025
University of New South Wales, Sydney, NSW.
Anxiety disorders are the most prevalent mental illness in Australia and are more common in women relative to men, as well as transgender and gender diverse people relative to cisgender people. Sex and gender differences in anxiety prevalence are likely driven by a combination of factors including differential exposure to different types of stressors and trauma, gendered enculturation of different coping responses and perceived stigma of mental illness, differences in medical comorbidities, and differences in symptom presentations. The established impact of gonadal hormone changes on anxiety risk and symptom presentation across the female lifespan underscore the need for sex- and gender-responsive management of anxiety disorders.
View Article and Find Full Text PDFTick-borne infections in patients under anti-CD20 therapy: Challenges for diagnosis and treatment.
Mult Scler
September 2025
Department of Neurology, Medical University of Vienna, Vienna, Austria; Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria.